Literature DB >> 23094954

Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany.

Steffen T Simon1, Anna Maria Niemand, Hamid Benalia, Raymond Voltz, Irene J Higginson, Claudia Bausewein.   

Abstract

BACKGROUND: Opioids are the drugs of choice for management of breathlessness in advanced disease, but acute episodic breathlessness remains difficult to manage. New routes of opioid applications with quicker onset of action seem attractive for the management of episodic breathlessness.
OBJECTIVE: This study aimed to determine the acceptability and preference of different routes of opioid applications in patients suffering from breathlessness due to advanced disease.
DESIGN: The study consisted of structured face-to-face interviews with patients suffering from breathlessness due to lung cancer (LC), chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and motor neurone disease (MND). Images and explanation were used to illustrate six application forms (oral, inhaled, sublingual, intranasal, buccal, transmucosal).
RESULTS: Participants numbered 119 (UK n=48, Germany n=71), 60% male, mean age 67.7 years (SD 9.9); 50% suffered from COPD. Inhaled was the most accepted (87%) and preferred (68%) route of application, followed by sublingual (45%/13%) and intranasal (42%/8%). The oral was least accepted (24%) and least preferred (9%) although nearly all participants had previous experiences with it (97%). Ratings were similar in both countries but different for preferences of sublingual (UK>Germany) and intranasal (Germany>UK). In general, participants from the UK rated more often "yes" for acceptability of all routes compared to Germany.
CONCLUSION: Inhaled was the most accepted and preferred route of application, but no route seemed to be acceptable to all patients. Therefore, individual patient preferences should be explored before drug prescription to enhance compliance and convenience.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094954      PMCID: PMC3509360          DOI: 10.1089/jpm.2012.0249

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  19 in total

1.  Intranasal fentanyl for episodic breathlessness.

Authors:  Thomas Sitte; Claudia Bausewein
Journal:  J Pain Symptom Manage       Date:  2008-10-26       Impact factor: 3.612

2.  A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.

Authors:  Russell K Portenoy; Donald Taylor; John Messina; Lothar Tremmel
Journal:  Clin J Pain       Date:  2006 Nov-Dec       Impact factor: 3.442

3.  Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.

Authors:  Andrew Davies; Giovambattista Zeppetella; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Frederik Sjolund; Mariann Stenberg; Alison Buchanan
Journal:  Eur J Pain       Date:  2011-01-19       Impact factor: 3.931

4.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

5.  Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers.

Authors:  Sara Booth; Stella Silvester; Christopher Todd
Journal:  Palliat Support Care       Date:  2003-12

6.  Characteristics and correlates of dyspnea in patients with advanced cancer.

Authors:  Suresh K Reddy; Henrique A Parsons; Ahmed Elsayem; J Lynn Palmer; Eduardo Bruera
Journal:  J Palliat Med       Date:  2009-01       Impact factor: 2.947

Review 7.  The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy.

Authors:  Sara Booth; Shakeeb H Moosavi; Irene J Higginson
Journal:  Nat Clin Pract Oncol       Date:  2008-02

Review 8.  Management of dyspnea in advanced motor neuron diseases.

Authors:  Vilma Adriana Tripodoro; Eduardo Luis De Vito
Journal:  Curr Opin Support Palliat Care       Date:  2008-09       Impact factor: 2.302

9.  Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.

Authors:  Amy P Abernethy; David C Currow; Peter Frith; Belinda S Fazekas; Annie McHugh; Chuong Bui
Journal:  BMJ       Date:  2003-09-06

Review 10.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

View more
  5 in total

1.  Does nebulized fentanyl relieve dyspnea during exercise in healthy man?

Authors:  Houssam G Kotrach; Jean Bourbeau; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2015-03-12

2.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Anil Chauhan; Nikita Jaiswal
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

Review 3.  Symptom management in the older adult: 2015 update.

Authors:  Thomas J Smith
Journal:  Clin Geriatr Med       Date:  2015-03-03       Impact factor: 3.076

Review 4.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Kiran K Thumburu
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

Review 5.  Inhaled opioids for cancer pain relief: A narrative review.

Authors:  Magdalena Osowicka; Piotr Janowiak; Agnieszka Gorzewska; Monika Lichodziejewska-Niemierko
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.